Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future

James R. Gavin; Clifford j. Bailey

doi:10.1089/dia.2023.0057

Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future

James R. Gavin
, Clifford j. Bailey^*

^*Corresponding author for this work

Emory University School of Medicine, Atlanta, Georgia, USA.
Senior Lecturer, School of Life and Health Sciences, ARCHA, Aston University, Birmingham. United Kingdom.

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

85 Downloads (Pure)

Abstract

Randomized controlled trials, which are considered the highest level of scientific evidence, have shown significant glycemic benefits associated with use of continuous glucose monitoring (CGM) in individuals with diabetes who are treated with intensive insulin regimens. However, numerous prospective, retrospective, and observational studies have investigated the impact of CGM in various diabetes populations treated with nonintensive therapies. Results from these studies have contributed to changes in payer coverage, prescriber behaviors, and expanding use of CGM. This article reviews findings from recent real-world studies, highlights the key lessons learned from these studies, and discusses how we need to move forward in increasing utilization of and access to CGM among all diabetes patients who would benefit from this technology.

Original language	English
Pages (from-to)	S5-S13
Number of pages	9
Journal	Diabetes Technology & Therapeutics
Volume	25
Issue number	S3
DOIs	https://doi.org/10.1089/dia.2023.0057
Publication status	Published - 1 Jun 2023

Bibliographical note

Copyright © Mary Ann Liebert, Inc., publishers, 2023. This is the accepted version of the following article: James R. Gavin III and Clifford J. Bailey. Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future. which has now been formally published in final form at Diabetes Technology & Therapeutics Jun 2023.S-5-S-13 at https://doi.org/10.1089/dia.2023.0057 . This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

Funding

Funding for the development of this article was provided by Abbott Diabetes Care.

Funders
Abbott Diabetes Care

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

continuous glucose monitoring
CGM
type 1 diabetes
type 2 diabetes
real-world evidence
Prospective

Access to Document

10.1089/dia.2023.0057

Continuous glucose monitoring impact
This is the accepted version of the following article: James R. Gavin III and Clifford J. Bailey. Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future. which has now been formally published in final form at Diabetes Technology & Therapeutics Jun 2023.S-5-S-13 at https://doi.org/10.1089/dia.2023.0057 . This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.
Accepted author manuscript, 257 KB

Cite this

@article{8b99eaef77bd464e99fb78135082cfc6,

title = "Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future",

abstract = "Randomized controlled trials, which are considered the highest level of scientific evidence, have shown significant glycemic benefits associated with use of continuous glucose monitoring (CGM) in individuals with diabetes who are treated with intensive insulin regimens. However, numerous prospective, retrospective, and observational studies have investigated the impact of CGM in various diabetes populations treated with nonintensive therapies. Results from these studies have contributed to changes in payer coverage, prescriber behaviors, and expanding use of CGM. This article reviews findings from recent real-world studies, highlights the key lessons learned from these studies, and discusses how we need to move forward in increasing utilization of and access to CGM among all diabetes patients who would benefit from this technology.",

keywords = "continuous glucose monitoring, CGM, type 1 diabetes, type 2 diabetes, real-world evidence, Prospective",

author = "Gavin, \{James R.\} and Bailey, \{Clifford j.\}",

note = "Copyright {\textcopyright} Mary Ann Liebert, Inc., publishers, 2023. This is the accepted version of the following article: James R. Gavin III and Clifford J. Bailey. Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future. which has now been formally published in final form at Diabetes Technology \& Therapeutics Jun 2023.S-5-S-13 at https://doi.org/10.1089/dia.2023.0057 . This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers{\textquoteright} self-archiving terms and conditions. ",

year = "2023",

month = jun,

day = "1",

doi = "10.1089/dia.2023.0057",

language = "English",

volume = "25",

pages = "S5--S13",

journal = "Diabetes Technology \& Therapeutics",

issn = "1520-9156",

publisher = "SAGE",

number = "S3",

}

TY - JOUR

T1 - Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future

AU - Gavin, James R.

AU - Bailey, Clifford j.

N1 - Copyright © Mary Ann Liebert, Inc., publishers, 2023. This is the accepted version of the following article: James R. Gavin III and Clifford J. Bailey. Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future. which has now been formally published in final form at Diabetes Technology & Therapeutics Jun 2023.S-5-S-13 at https://doi.org/10.1089/dia.2023.0057 . This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Randomized controlled trials, which are considered the highest level of scientific evidence, have shown significant glycemic benefits associated with use of continuous glucose monitoring (CGM) in individuals with diabetes who are treated with intensive insulin regimens. However, numerous prospective, retrospective, and observational studies have investigated the impact of CGM in various diabetes populations treated with nonintensive therapies. Results from these studies have contributed to changes in payer coverage, prescriber behaviors, and expanding use of CGM. This article reviews findings from recent real-world studies, highlights the key lessons learned from these studies, and discusses how we need to move forward in increasing utilization of and access to CGM among all diabetes patients who would benefit from this technology.

AB - Randomized controlled trials, which are considered the highest level of scientific evidence, have shown significant glycemic benefits associated with use of continuous glucose monitoring (CGM) in individuals with diabetes who are treated with intensive insulin regimens. However, numerous prospective, retrospective, and observational studies have investigated the impact of CGM in various diabetes populations treated with nonintensive therapies. Results from these studies have contributed to changes in payer coverage, prescriber behaviors, and expanding use of CGM. This article reviews findings from recent real-world studies, highlights the key lessons learned from these studies, and discusses how we need to move forward in increasing utilization of and access to CGM among all diabetes patients who would benefit from this technology.

KW - continuous glucose monitoring

KW - CGM

KW - type 1 diabetes

KW - type 2 diabetes

KW - real-world evidence

KW - Prospective

UR - https://www.liebertpub.com/doi/10.1089/dia.2023.0057

UR - https://www.scopus.com/pages/publications/85162887263

U2 - 10.1089/dia.2023.0057

DO - 10.1089/dia.2023.0057

M3 - Article

SN - 1520-9156

VL - 25

SP - S5-S13

JO - Diabetes Technology & Therapeutics

JF - Diabetes Technology & Therapeutics

IS - S3

ER -

Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this